OMass Therapeutics appoints Jonathan Montagu as Non-Executive Director

OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines, today announced the appointment of Jonathan Montagu as a Non-Executive Director. Jonathan brings more than 20 years of leadership experience in both biotechnology and high-technology industries.


“We are delighted to welcome Jonathan to our Board of Directors,” said Dr Edward Hodgkin, Chairman, OMass Therapeutics and Partner at Syncona Investment Management Limited. “Jonathan is a highly accomplished leader in our industry with extensive experience in building chemistry platform companies. We look forward to drawing on his expertise as we develop a pipeline of differentiated therapeutics that leverage OMass’ unique ability to interrogate the biology of intact protein complexes using mass spectrometry.”  

Jonathan Montagu, commented:

“I am delighted to join the Board of Directors of OMass at an exciting time in the company’s development. Native mass spectrometry can be used to generate a high resolution, biophysical map of protein structure and interactions and I look forward to helping the Company to leverage this capability to bring transformative therapies to the clinic and make a difference in the lives of patients.”

Jonathan is the Co-Founder and Chief Executive Officer of HotSpot Therapeutics, a company targeting nature’s regulatory mechanisms to create high precision allosteric medicines for the treatment of serious autoimmune and metabolic diseases. Prior to co-founding HotSpot, Jonathan served as Chief Business Officer at Nimbus Therapeutics, where he helped establish the company’s drug discovery platform and pipeline. He also served as Vice President, Business Development at Concert Pharmaceuticals, and was instrumental in securing a $1B multi-product transaction for the company with GSK.

Jonathan trained as a chemist at Oxford University, Cold Spring Harbor Laboratory, The Scripps Research Institute, and Cancer Research UK.

OMass Therapeutics was formed in 2016 as a spin-out from the University of Oxford and completed a £14 million Series A financing in 2018 from Syncona and Oxford Sciences Innovation. OMass applies structural mass spectrometry technology developed in the laboratory of Prof. Dame Carol Robinson to the discovery of novel therapeutics against complex protein targets, including membrane proteins.

Back to News and insights